Business Context and Reporting Period
This Form 8-K is filed by TenX Keane Acquisition (the "Company"), a Cayman Islands corporation, on May 17, 2024. The Company is an emerging growth company engaged in a business combination with Citius Oncology, Inc. The filing reports on a specific transaction executed on May 17, 2024, to extend the deadline for consummating this merger.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial metric disclosed is a direct financial obligation created on the reporting date:
- Extension Contribution: $66,667 deposited into the Company's trust account by Citius Pharma (designee of the Sponsor).
- Debt Instrument: An unsecured, non-interest-bearing promissory note issued by the Company in the principal amount of $66,667 to Citius Pharma.
Material Changes
The primary material change is the extension of the business combination deadline. Previously extended once on April 26, 2024, the Company has now extended the timeline for a second time:
- Previous Deadline: May 18, 2024.
- New Deadline: June 18, 2024.
- Extension Cost: The extension was funded by the $66,667 contribution, which is the lesser of $66,667 or $0.03 per public share.
Outlook, Risks, and Contingencies
The Company's ability to complete its initial business combination is contingent upon meeting the new deadline of June 18, 2024. The filing notes that the Company has the ability to extend the timeline up to seven times total (from the original April 18, 2024 date) through November 18, 2024, provided the Sponsor or its designee deposits the required funds for each monthly extension. The promissory note issued for the current extension is repayable in full per the terms of the Merger Agreement dated October 23, 2023.
Investor Verification Checklist
- Verify the status of the Merger Agreement with Citius Oncology, Inc. and whether the June 18, 2024 deadline is sufficient for regulatory approvals.
- Confirm the total number of extensions utilized (2 of 7 possible) and the remaining extension capacity.
- Review the terms of the unsecured promissory note (Exhibit 10.1) regarding repayment conditions upon the consummation or termination of the business combination.
- Check the balance of the trust account to ensure it remains sufficient for potential redemptions or the completion of the merger.